Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Open access
Peng, Zhi, Liu, Tianshu, Wei, Jia, Wang, Airong, He, Yifu, Yang, Liuzhong, Zhang, Xizhi, Fan, Nanfeng, Luo, Suxia, Li, Zhen, Gu, Kangsheng, Lu, Jianwei, Xu, Jianming, Fan, Qingxia, Xu, Ruihua, Zhang, Liangming, Li, Enxiao, Sun, Yuping, Yu, Guohua, Bai, Chunmei, Liu, Yong, Zeng, Jiangzheng, Ying, Jieer, Liang, Xinjun, Xu, Nong, Gao, Chao, Shu, Yongqian, Ma, Dong, Dai, Guanghai, Li, Shengmian, Deng, Ting, Cui, Yuehong, Fang, Jianmin, Ba, Yi, Shen, Lin·2021·Cancer Communications

Abstract

Background: Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC) 2+ and fluorescence in‐situ hybridization‐negative patients. Here, we report the efficacy and safety of a novel anti‐HER2 antibody RC48 for patients with HER2‐overexpressing, advanced gastric or gastroesophageal junction cancer. Methods: Patients with HER2‐overexpressing (IHC 2+ or 3+), locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second‐line therapy were eligible and received RC48 2.5 mg/kg alone every 2 weeks. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), duration of response, time to progression, disease control rate, and safety. Results: Of 179 patients screened, 125 were eligible and received RC48 treatment. The ORR was 24.8% (95% confidence interval [CI]: 17.5%‐33.3%). The median PFS and OS were 4.1 months (95% CI: 3.7‐4.9 months) and 7.9 months (95% CI: 6.7‐9.9 months), respectively. The most frequently reported adverse events were decreased white blood cell count (53.6%), asthenia (53.6%), hair loss (53.6%), decreased neutrophil count (52.0%), anemia (49.6%), and increased aspartate aminotransferase level (43.2%). Serious adverse events (SAEs) occurred in 45 (36.0%) patients, and RC48‐related SAEs were mainly decreased neutrophil count (3.2%). Seven patients had adverse events that led to death were not RC48‐related. Conclusions: RC48 showed promising activity with manageable safety, suggesting potential application in patients with HER2‐overexpressing, advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cac2.12214

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 210

Metadata

Authors
Peng, Z., Liu, T., Wei, J., Wang, A., He, Y., Yang, L., Zhang, X., Fan, N., Luo, S., Li, Z., Gu, K., Lu, J., Xu, J., Fan, Q., Xu, R., Zhang, L., Li, E., Sun, Y., Yu, G., Bai, C., Liu, Y., Zeng, J., Ying, J., Liang, X., Xu, N., Gao, C., Shu, Y., Ma, D., Dai, G., Li, S., Deng, T., Cui, Y., Fang, J., Ba, Y., & Shen, L.
Venue
Cancer Communications
Published
2021-10-19
Volume
41
Issue
11
Pages
1173-1182
ISSN
  • 1000-467X (ISSN-L)
  • 2523-3548
OpenAlex
W3206805169
Cited by
210
References
4
FWCI
17.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.